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Introduction {#jah32066-sec-0004}
============

Cataracts are the main cause of low vision and blindness worldwide.[1](#jah32066-bib-0001){ref-type="ref"} Nearly 13 million people in the United States are reported to suffer from cataracts.[2](#jah32066-bib-0002){ref-type="ref"} Statins are widely prescribed to treat hyperlipidemia, as they reduce the risk of cardiovascular disease by inhibiting 3‐hydroxy‐3‐methyl‐glutaryl‐CoA reductase.[3](#jah32066-bib-0003){ref-type="ref"}, [4](#jah32066-bib-0004){ref-type="ref"} Although it has been established that statins can significantly reduce cardiovascular mortality,[5](#jah32066-bib-0005){ref-type="ref"}, [6](#jah32066-bib-0006){ref-type="ref"}, [7](#jah32066-bib-0007){ref-type="ref"}, [8](#jah32066-bib-0008){ref-type="ref"} some adverse effects related to statins have been recognized because of their increasing use.[9](#jah32066-bib-0009){ref-type="ref"}, [10](#jah32066-bib-0010){ref-type="ref"}

Concern about the cataractogenic effect of statins arose from animal studies in which dogs were administered high doses of statins, such as simvastatin, fluvastatin, and lovastatin.[10](#jah32066-bib-0010){ref-type="ref"}, [11](#jah32066-bib-0011){ref-type="ref"} However, in human studies, investigations into the association between statin use and the incidence of cataracts and cataract surgery have yielded inconsistent and conflicting results.[12](#jah32066-bib-0012){ref-type="ref"}, [13](#jah32066-bib-0013){ref-type="ref"}, [14](#jah32066-bib-0014){ref-type="ref"}, [15](#jah32066-bib-0015){ref-type="ref"}, [16](#jah32066-bib-0016){ref-type="ref"}, [17](#jah32066-bib-0017){ref-type="ref"}, [18](#jah32066-bib-0018){ref-type="ref"}, [19](#jah32066-bib-0019){ref-type="ref"}, [20](#jah32066-bib-0020){ref-type="ref"}, [21](#jah32066-bib-0021){ref-type="ref"}, [22](#jah32066-bib-0022){ref-type="ref"} Some studies have reported no association between statin use and cataracts,[12](#jah32066-bib-0012){ref-type="ref"}, [13](#jah32066-bib-0013){ref-type="ref"}, [14](#jah32066-bib-0014){ref-type="ref"}, [23](#jah32066-bib-0023){ref-type="ref"}, [24](#jah32066-bib-0024){ref-type="ref"}, [25](#jah32066-bib-0025){ref-type="ref"}, [26](#jah32066-bib-0026){ref-type="ref"} whereas others have found that statin use is protective against the incidence of cataracts,[15](#jah32066-bib-0015){ref-type="ref"}, [16](#jah32066-bib-0016){ref-type="ref"}, [27](#jah32066-bib-0027){ref-type="ref"} or that it is associated with an increased risk of cataracts.[17](#jah32066-bib-0017){ref-type="ref"}, [18](#jah32066-bib-0018){ref-type="ref"}, [19](#jah32066-bib-0019){ref-type="ref"}, [20](#jah32066-bib-0020){ref-type="ref"}, [21](#jah32066-bib-0021){ref-type="ref"}, [22](#jah32066-bib-0022){ref-type="ref"} To address this issue, Kostis et al[28](#jah32066-bib-0028){ref-type="ref"} performed a meta‐analysis in 2013. However, they combined the unadjusted odds ratio directly without considering potential confounding factors in some studies, which may have led to inaccurate results. In addition, some studies have been published in the 2 years since the study by Kostis et al[28](#jah32066-bib-0028){ref-type="ref"} was published, of which most yielded results that conflicted with those included in Kostis et al.[18](#jah32066-bib-0018){ref-type="ref"}, [19](#jah32066-bib-0019){ref-type="ref"}, [21](#jah32066-bib-0021){ref-type="ref"}, [22](#jah32066-bib-0022){ref-type="ref"} Therefore, we performed a new meta‐analysis to investigate the association between statin use and cataracts.

Methods {#jah32066-sec-0005}
=======

We conducted this meta‐analysis following the guidance provided by the Cochrane Handbook[29](#jah32066-bib-0029){ref-type="ref"} and Kanwal and White.[30](#jah32066-bib-0030){ref-type="ref"} Two authors (Yu and Chu) independently performed the literature search, article screening, study selection, quality evaluation, and data extraction. Disagreements were resolved by discussion, and a consensus was achieved in the selection of the articles for analysis.

Search Strategy {#jah32066-sec-0006}
---------------

The Cochrane Library, PubMed, and EMBASE databases were searched from January 1980 to January 2016 for English language publications, including abstracts. The search was performed using the following terms: "statins OR HMG‐CoA reductase inhibitors OR Simvastatin OR Lovastatin OR Fluvastatin OR Pravastatin OR Rosuvastatin OR Atorvastatin" AND "cataract." We also manually searched for relevant articles from the reference lists of the retrieved articles. When the available information was incomplete, we attempted to contact the study investigators for additional information.

Study Selection {#jah32066-sec-0007}
---------------

Studies were included in this meta‐analysis if they fulfilled the following criteria: (1) the study was a case--control, cohort study, or randomized controlled trials (RCTs); (2) non--statin users were included in the comparison group; (3) cataracts and/or cataract surgery was an outcome; (4) the association between statin use and the risk of cataracts/cataract surgery was investigated; (5) risk estimates of morbidity and 95% CIs were reported or the information required to calculate them was available. Basic science studies, reviews, editorials/letters, case reports, and studies without comparison groups were excluded.

Data Extraction and Quality Assessment {#jah32066-sec-0008}
--------------------------------------

Data extraction was performed independently by 2 of the authors (Yu and Chu). The following information was extracted from each study: the last name of the first author, year of publication, study design, country of origin of the population studied, patient characteristics, statin use, information source for exposure ascertainment, risk estimates and corresponding 95% CIs, and covariates adjusted for in the multivariable analysis. For studies that provided more than 1 risk estimate, we extracted the estimate that was adjusted for the greatest number of confounding factors. We assessed the methodological quality of the included studies based on the Newcastle‐Ottawa Scale (NOS) for observational studies,[31](#jah32066-bib-0031){ref-type="ref"} which was developed to assess the quality of nonrandomized studies in meta‐analysis. Using this scale, observational studies were scored across 3 categories as follows: selection (4 questions) and comparability (2 questions) of the study group and ascertainment of the outcome of interest (3 questions), with all questions having a score of 1 except for the comparability of study groups, for which separate points were awarded for controlling for age and/or sex (maximum, 2 points). A score of ≥7 points was suggestive of a high‐quality study. The quality of the included RCTs was assessed by Cochrane risk of bias assessment,[29](#jah32066-bib-0029){ref-type="ref"} which allots scores for the following: random sequence generation (1), allocation concealment (1), blinding of participants and personnel (1), blinding of outcome assessment (1), incomplete outcome data (1), selective reporting (1), and other sources of bias (1). Scores of 1 to 4 indicate low quality, and scores of 5 to 7 indicate high quality.

Outcomes Assessed {#jah32066-sec-0009}
-----------------

The primary analysis focused on assessing the risk of cataracts and cataract surgery among users of statins. We also performed subgroup analyses based on study design (case--control, cohort, or RCT), type of statin, the methodological quality of the study (high or low), study location (Europe, North America, Asia or Australia), age, sex, follow‐up duration, outcome and outcome assessment, and whether potential confounders were included in the adjusting model (eg, low‐density lipoprotein included/missing, cardiovascular disease \[CVD\] included/missing, smoking included/missing).

Statistical Analysis {#jah32066-sec-0010}
--------------------

STATA 12.0 software (StataCorp LP, College Station, TX) was used for statistical analysis. Heterogeneity was assessed using the Cochran Q χ^2^ test and the I^2^ statistic.[32](#jah32066-bib-0032){ref-type="ref"} An I^2^ value of \>50% or a *P* value of \<0.05 for the Q‐statistic indicated significant heterogeneity.[33](#jah32066-bib-0033){ref-type="ref"} Adjusted effect estimates (odds ratios, relative risks \[RRs\], and hazard risks) between the outcome and use of statins were extracted. In the presence of heterogeneity, we used a random‐effects model because its assumptions account for the presence of variability among studies. The association between statin use and cataract or cataract surgery risk was estimated using the RRs and corresponding 95% CIs. Because the outcomes were relatively uncommon and the odds ratios in the case--control studies were close to 1, odds ratios were considered approximations of RR.[34](#jah32066-bib-0034){ref-type="ref"}

Results {#jah32066-sec-0011}
=======

Search Results {#jah32066-sec-0012}
--------------

By searching the 3 databases, 615 potentially eligible articles were identified. In total, 489 articles were excluded after reading the title and abstract, and the full texts of the remaining 120 articles were evaluated in detail. Of these 120 articles, 16 met our inclusion criteria. One of these articles included 2 studies.[21](#jah32066-bib-0021){ref-type="ref"} In total, 17 studies consisting of 6 cohort studies, 6 case--control studies, and 5 RCTs were included in the meta‐analysis and involved more than 313 200 cataract cases. The number of articles according to reason for exclusion at each stage of the eligibility assessment is outlined in Figure [1](#jah32066-fig-0001){ref-type="fig"}.

![Flow chart of the studies considered and selected for review. RCTs indicates randomized controlled trials.](JAH3-6-e004180-g001){#jah32066-fig-0001}

Characteristics of the Included Studies {#jah32066-sec-0013}
---------------------------------------

The main characteristics of the cohort and case--control studies are shown in Tables [1](#jah32066-tbl-0001){ref-type="table-wrap"} and [2](#jah32066-tbl-0002){ref-type="table-wrap"}. Among the cohort studies, 3 studies were performed in North America, and the remaining 3 studies were performed in Europe, Asia, and Australia.[15](#jah32066-bib-0015){ref-type="ref"}, [16](#jah32066-bib-0016){ref-type="ref"}, [17](#jah32066-bib-0017){ref-type="ref"}, [18](#jah32066-bib-0018){ref-type="ref"}, [19](#jah32066-bib-0019){ref-type="ref"}, [20](#jah32066-bib-0020){ref-type="ref"} Among the case--control studies, 4 studies were performed in North America, and 2 were performed in Europe.[12](#jah32066-bib-0012){ref-type="ref"}, [13](#jah32066-bib-0013){ref-type="ref"}, [14](#jah32066-bib-0014){ref-type="ref"}, [21](#jah32066-bib-0021){ref-type="ref"}, [22](#jah32066-bib-0022){ref-type="ref"} The extent of adjustment for potential clinical risk factors varied considerably across the cohort and case--control studies (Table [S1](#jah32066-sup-0001){ref-type="supplementary-material"}). Based on the methodological quality assessment scores (Tables [S2](#jah32066-sup-0001){ref-type="supplementary-material"} and [S3](#jah32066-sup-0001){ref-type="supplementary-material"}), the mean score of the 6 cohort studies included in the analysis was 7. Four studies were of high quality (NOS ≥7), and 3 studies were of low quality (NOS \<7). The mean score of the 6 case--control studies was 6.5. Three studies were of high quality (NOS ≥7), and 3 studies were of low quality (NOS \<7). The characteristics of the RCTs are shown in Table [3](#jah32066-tbl-0003){ref-type="table-wrap"}.[23](#jah32066-bib-0023){ref-type="ref"}, [24](#jah32066-bib-0024){ref-type="ref"}, [25](#jah32066-bib-0025){ref-type="ref"}, [26](#jah32066-bib-0026){ref-type="ref"}, [27](#jah32066-bib-0027){ref-type="ref"} Two trials were performed in the United States, and 3 trials were performed in Europe. The mean score of the RCTs included in the analysis was 5.4 (Table [S4](#jah32066-sup-0001){ref-type="supplementary-material"}).

###### 

Characteristics of the Cohort Studies

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study, Year                                                   Location   Follow‐Up Period, y   Age (Mean), y     Outcome            Outcome Assessment                  Ascertainment of Statins Exposure   Cases, n    Controls, n     Overall Quality
  ------------------------------------------------------------- ---------- --------------------- ----------------- ------------------ ----------------------------------- ----------------------------------- ----------- --------------- -----------------
  Klein, 2006[15](#jah32066-bib-0015){ref-type="ref"}           US         5                     63.2              Cataract           Wisconsin Cataract Grading System   Private census                      185/834     42/214          7

  Tan, 2007[16](#jah32066-bib-0016){ref-type="ref"}             AUS        \>5                   ≥50 (\>60)        Cataract\          Wisconsin Cataract Grading System   Questionnaires                      17/72       365/1152        6
                                                                                                                   Cataract surgery                                                                                                       

  Hippisley‐Cox, 2010[17](#jah32066-bib-0017){ref-type="ref"}   UK         \<5                   30 to 84 (\<60)   Cataract           Medical records                     Drug prescription\                  36 541      2 004 692       8
                                                                                                                                                                          Computerized record                                             

  Waudby, 2011[20](#jah32066-bib-0020){ref-type="ref"}          US         \>5                   \>60              Cataract\          ICD‐9\                              Drug prescription\                  1959/7470   1645/12 579     6
                                                                                                                   Cataract surgery   CPT code                            Computerized record                                             

  Lai, 2013[19](#jah32066-bib-0019){ref-type="ref"}             Asia       \>5                   70.4              Cataract surgery   ICD‐9                               Drug prescription\                  1533/6830   16 137/43 335   8
                                                                                                                                                                          Computerized record                                             

  Leuschen, 2013[18](#jah32066-bib-0018){ref-type="ref"}        US         \<5                   30 to 85 (\<60)   Cataract           ICD‐9                               Drug prescription\                  2477/6972   2337/6972       7
                                                                                                                                                                          Computerized record                                             
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CPT indicates current procedural terminology; ICD, International Classification of Diseases.

John Wiley & Sons, Ltd

###### 

Characteristics of the Case--Control Studies

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study, Year                                                Location   Follow‐Up Period, y   Age (Mean), y     Outcome            Outcome Assessment                Ascertainment of Statins Exposure   Cases, n   Controls, n   Overall Quality
  ---------------------------------------------------------- ---------- --------------------- ----------------- ------------------ --------------------------------- ----------------------------------- ---------- ------------- -----------------
  Schlienger, 2001[12](#jah32066-bib-0012){ref-type="ref"}   UK         \<5                   40 to 79 (\>60)   Cataract\          ICD‐8, OMXIS procedure code 156   Drug prescription\                  7405       28 327        7
                                                                                                                Cataract surgery                                     Computerized record                                          

  Smeeth, 2003[13](#jah32066-bib-0013){ref-type="ref"}       UK         \<5                   ≥40 (75)          Cataract           ICD‐8                             Drug prescription\                  15 479     15 479        7
                                                                                                                                                                     Computerized record                                          

  Fong, 2012[14](#jah32066-bib-0014){ref-type="ref"}         US         \<5                   ≥50 (\>60)        Cataract surgery   CPT code                          Drug prescription\                  13 583     34 049        6
                                                                                                                                                                     Computerized record                                          

  Wise‐BC, 2014[21](#jah32066-bib-0021){ref-type="ref"}      Canada     \<5                   \>70              Cataract\          Computerized record               Drug prescription\                  162 501    650 004       6
                                                                                                                Cataract surgery                                     Computerized record                                          

  Wise‐IMS, 2014[21](#jah32066-bib-0021){ref-type="ref"}     Canada     \<5                   40 to 85 (\>70)   Cataract\          Computerized record               Drug prescription\                  45 065     450 650       7
                                                                                                                Cataract surgery                                     Computerized record                                          

  Erie, 2016[22](#jah32066-bib-0022){ref-type="ref"}         US         \<5                   ≥50 (\>60)        Cataract Surgery   ICD‐9\                            Drug prescription\                  6024       6024          6
                                                                                                                                   CPT code                          Computerized record                                          
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CPT indicates current procedural terminology; ICD, International Classification of Diseases; OMXIS, Oxford Medical Information System.

John Wiley & Sons, Ltd

###### 

Characteristics of RCTs

  Study, Year                                                            Location   Study Design   Follow‐Up Period   Age (Mean), y                                          Outcome                         Outcome Assessment      Type of Statins              Cases/Statins Group                             Cases/Control Group
  ---------------------------------------------------------------------- ---------- -------------- ------------------ ------------------------------------------------------ ------------------------------- ----------------------- ---------------------------- ----------------------------------------------- -----------------------------------------------
  Laties, 1991[23](#jah32066-bib-0023){ref-type="ref"}                   US         RCT            48 weeks           18 to 70 (\<60)                                        Cataract surgery                Slit‐lamp examination   Lovastatin                   25/6582                                         7/1663
  Harris, 1995[24](#jah32066-bib-0024){ref-type="ref"}                   EU         RCT            18 months          40 to 75 (\>60)                                        Cataract and Cataract surgery   OXGRAE                  Simvastatin                  30/414                                          10/207
  Pederson, 1996[25](#jah32066-bib-0025){ref-type="ref"}                 EU         RCT            5.4 years          35 to 70 (\>60)                                        Cataract                        Slit‐lamp examination   Simvastatin                  66/2221                                         53/2223
  Heart protection study, 2002[26](#jah32066-bib-0026){ref-type="ref"}   US         RCT            5 years            40 to 80 (NA)[a](#jah32066-note-0006){ref-type="fn"}   Cataract                        Medical records         Simvastatin                  393/10 232                                      404/10 237
  Bang, 2015[27](#jah32066-bib-0027){ref-type="ref"}                     US         RCT            4.3 years          45 to 85 (\>60)                                        Cataract                        Medical records         Simvastatin plus Ezetimibe   NA/944[b](#jah32066-note-0007){ref-type="fn"}   NA/929[b](#jah32066-note-0007){ref-type="fn"}

RCTs indicates randomized controlled trials; NA indicates not available; OXGRADE, Oxford grading system.

The authors did not show the mean age of subjects.

The authors showed the relative risk value instead of number of cases.

John Wiley & Sons, Ltd

Main Analysis {#jah32066-sec-0014}
-------------

The pooled RR of the cohort studies was 1.13 (95% CI, 1.01--1.25), which indicated that the use of statins was associated with a 13% increase in cataract incidence or cataract surgery (Figure [2](#jah32066-fig-0002){ref-type="fig"}). The I^2^ value indicated significant heterogeneity across the studies (I^2^=90.5%; *P*\<0.001). However, the pooled RRs of the case--control studies and RCTs were 1.10 (95% CI, 0.99--1.23) (Figure [3](#jah32066-fig-0003){ref-type="fig"}) and 0.89 (95% CI, 0.72--1.10) (Figure [4](#jah32066-fig-0004){ref-type="fig"}),[23](#jah32066-bib-0023){ref-type="ref"}, [24](#jah32066-bib-0024){ref-type="ref"}, [25](#jah32066-bib-0025){ref-type="ref"}, [26](#jah32066-bib-0026){ref-type="ref"}, [27](#jah32066-bib-0027){ref-type="ref"} which indicated that the use of statins was not associated with cataract incidence or cataract surgery. The I^2^ value of the case--control studies was 95.9%, which indicated significant heterogeneity across the studies. However, the I^2^ value of the RCTs was 30.5%, which indicated low heterogeneity across the RCTs. We also performed a sensitivity analysis for the cohort studies (Figure [S1](#jah32066-sup-0001){ref-type="supplementary-material"}), case--control studies (Figure [S2](#jah32066-sup-0001){ref-type="supplementary-material"}), and RCTs (Figure [S3](#jah32066-sup-0001){ref-type="supplementary-material"}), and the results showed that the sequential omission of individual studies did not alter the overall effect. The pooled estimate effect size changed from 1.07 (95% CI, 0.91--1.25) to 1.17 (95% CI, 1.06--1.25) for the cohort studies, from 1.06 (95% CI, 0.96--1.19) to 1.14 (95% CI, 1.03--1.28) for the case--control studies, and from 0.82 (95% CI, 0.58--1.15) to 0.96 (95% CI, 0.85--1.09) for the RCTs.

![Forest plot of the cohort studies. The pooled RR of the cohort studies was 1.13 (95% CI, 1.01--1.25). The I^2^ value indicated considerable heterogeneity across these cohort studies (I^2^=90.5%; *P*\<0.001). ES indicates effect size; RR, relative risk.](JAH3-6-e004180-g002){#jah32066-fig-0002}

![Forest plot of the case--control studies. The pooled RR of the case--control studies was 1.10 (95% CI, 0.99--1.23). The I^2^ value revealed considerable heterogeneity across these case--control studies (I^2^=95.9%; *P*\<0.001). ES indicates effect size; RR, relative risk.](JAH3-6-e004180-g003){#jah32066-fig-0003}

![Forest plot of the RCTs. The pooled RR of the RCTs was 0.89 (95% CI, 0.72--1.10). The I^2^ value indicated slight heterogeneity across these RCTs (I^2^=30.5%; *P*=0.218). ES indicates effect size; RCT, randomized controlled trial; RR, relative risk.](JAH3-6-e004180-g004){#jah32066-fig-0004}

Subgroup Meta‐Analyses {#jah32066-sec-0015}
----------------------

The results of the subgroup analyses of the cohort and case--control studies are presented in Tables [S5](#jah32066-sup-0001){ref-type="supplementary-material"} and [S6](#jah32066-sup-0001){ref-type="supplementary-material"}. In the subgroup analysis of cohort studies, there were significant associations in the subgroups of high methodological quality, outcome assessment, cataract, no older than 60, less than 5 years follow‐up duration, low‐density lipoprotein missing model, CVD included model, consultation rate included model, and hypertension included model. No associations were observed in the low methodological quality, studies performed in North America, older than 60 years, more than 5 years follow‐up duration, low‐density lipoprotein included model, CVD missing model, smoking missing model, consultation rate missing model, and hypertension missing model subgroups (Table [S5](#jah32066-sup-0001){ref-type="supplementary-material"}, Figures [S4 through S15](#jah32066-sup-0001){ref-type="supplementary-material"}). In the subgroup analysis of case--control studies, significant associations were observed in the subgroups of atorvastatin, lovastatin, high methodological quality, cataract surgery, CVD included model, smoking missing model, consultation rate missing model, and hypertension included model. No associations were observed in the fluvastatin, rosuvastatin, pravastatin, simvastatin, low methodological quality, studies performed in North America and Europe, outcome assessment, cataract and cataract surgery, CVD missing model, smoking included model, consultation rate included model, and hypertension missing model subgroups (Table [S6](#jah32066-sup-0001){ref-type="supplementary-material"}, Figures [S16 through S25](#jah32066-sup-0001){ref-type="supplementary-material"}).

The results of the subgroup analysis of RCTs are presented in Table [S7](#jah32066-sup-0001){ref-type="supplementary-material"}.

When the studies were grouped according to patient age, no association was observed in the older than 60 years subgroup (RR, 0.82; 95% CI, 0.53--1.26) and the no older than 60 years subgroup (RR, 0.97; 95% CI, 0.84--1.11) (Figure [S26](#jah32066-sup-0001){ref-type="supplementary-material"}). Although the mean age of the Heart Protection Study subjects was not presented, the results did not change regardless of which group we placed this study in (Figure [S27](#jah32066-sup-0001){ref-type="supplementary-material"}).

When we grouped the studies by follow‐up duration, no significant association was observed in the no more than 5 years group (RR, 0.86; 95% CI, 0.48--1.51) and in the more than 5 years group (RR, 0.95; 95% CI, 0.83--1.08) (Figure [S28](#jah32066-sup-0001){ref-type="supplementary-material"}).

Discussion {#jah32066-sec-0016}
==========

In this comprehensive meta‐analysis of 6 cohort, 6 case--control studies, and 5 RCTs, we analyzed the effect of statin use on the risk of cataracts in more than 313 200 patients. Analysis of the cohort studies showed that statin use was associated with a 13% increased risk of cataracts. However, analysis of the case--control studies and RCTs revealed no association between statin use and the risk of cataract. The effect size of the case--control studies was marginal, namely, RR=1.10 (95% CI, 0.99--1.23). Based on the differing characteristics of observational (case--control and cohort) studies and RCTs, such discordant results are not unexpected. Because of the rigorous criteria of RCTs, individuals at greatest risk for adverse events may be excluded. Furthermore, the subjects of RCTs may be healthier than the subjects of observational studies.[35](#jah32066-bib-0035){ref-type="ref"} The RCTs in this analysis had good internal validity, but the external validity was limited. The conclusion could not be extended to the whole population. In a population similar to the study population, the conclusion was reliable. Moreover, there may be a large portion of patients similar to the patients enrolled in these RCTs. However, there are also many patients who are not similar to the patients enrolled in these RCTs. The observational studies involve more cases with different health conditions. However, in observational studies, baseline confounders can be present, which may affect the results. In such studies, relative to non--statin users, statin users may be expected to be of poorer health or to have higher risk factors that necessitate statin therapy. As a result, adverse event rates may be higher among statin users. Although most observational studies (including the present meta‐analysis) have attempted to characterize their patients and identify validated markers of morbidity and mortality, potential unidentified confounders may exist.[35](#jah32066-bib-0035){ref-type="ref"}, [36](#jah32066-bib-0036){ref-type="ref"} This may lead to a calculated effect size that is slightly higher than the real one. Therefore, the real effect may be no significant association.

The analyses of cohort and case--control studies were limited by the considerable heterogeneity across studies. In the subgroup analysis of cohort studies, the I^2^ values decreased significantly when subgrouped by sex, outcome assessment, age, follow‐up duration, or consultation rate included/missing model (Table [S5](#jah32066-sup-0001){ref-type="supplementary-material"}, Figures [S6](#jah32066-sup-0001){ref-type="supplementary-material"}, [S7](#jah32066-sup-0001){ref-type="supplementary-material"}, [S9](#jah32066-sup-0001){ref-type="supplementary-material"}, [S10](#jah32066-sup-0001){ref-type="supplementary-material"}, and [S14](#jah32066-sup-0001){ref-type="supplementary-material"}). In the female (Figure [S6B](#jah32066-sup-0001){ref-type="supplementary-material"}), no older than 60 years (Figure [S9B](#jah32066-sup-0001){ref-type="supplementary-material"}), and less than 5 years follow‐up subgroups (Figure [S10B](#jah32066-sup-0001){ref-type="supplementary-material"}), the I^2^ values decreased because the weight of Cox\'s study was much higher (more than 70%). In the consultation rate included model subgroup (Figure [S14A](#jah32066-sup-0001){ref-type="supplementary-material"}), the I^2^ value decreased because the weight of Lai\'s study was much higher (more than 80%). Consequently, the heterogeneity may be partly attributed to the outcome assessment. The evaluation criterion of various assessment methods may have varied among the studies, and patients diagnosed with cataracts by 1 method may not be so diagnosed when another method is used. Furthermore, even when the same method for diagnosis is used, different physicians may make different decisions, especially regarding cataract surgery. In the subgroup analysis of case--control studies, the I^2^ values were significantly decreased when subgrouped by quality assessment, study location, type of statin, CVD included/missing model, smoking included/missing model, consultation rate included/missing model, or hypertension included/missing model (Table [S6](#jah32066-sup-0001){ref-type="supplementary-material"}, Figures [S16](#jah32066-sup-0001){ref-type="supplementary-material"}, [S17](#jah32066-sup-0001){ref-type="supplementary-material"}, [S19](#jah32066-sup-0001){ref-type="supplementary-material"}, [S21](#jah32066-sup-0001){ref-type="supplementary-material"}, [S22](#jah32066-sup-0001){ref-type="supplementary-material"}, [S23](#jah32066-sup-0001){ref-type="supplementary-material"}, and [S25](#jah32066-sup-0001){ref-type="supplementary-material"}). In the quality assessment and hypertension included/missing model subgroups, the I^2^ values of the high quality group (Figure [S16A](#jah32066-sup-0001){ref-type="supplementary-material"}) and the hypertension missing model (Figure [S25B](#jah32066-sup-0001){ref-type="supplementary-material"}) decreased because the weights of the Wise‐IMS study (more than 95%) and the Fong study (more than 70%) were much higher than those of the other studies. In the subgroup analyses of the study performed in Europe (Figure [S17B](#jah32066-sup-0001){ref-type="supplementary-material"}), the CVD missing model (Figure [S21B](#jah32066-sup-0001){ref-type="supplementary-material"}), and the consultation rate included model (Figure [S23A](#jah32066-sup-0001){ref-type="supplementary-material"}), the I^2^ values decreased because the included studies were derived from the same database. Therefore, the heterogeneity may be partly attributed to the types of statins. Statins have extensive pleotropic effects that extend beyond their cholesterol‐lowering properties.[35](#jah32066-bib-0035){ref-type="ref"}, [37](#jah32066-bib-0037){ref-type="ref"} Different types of statins may affect cataract development by different mechanisms. Therefore, patients taking different statins may have different risks for developing cataracts. In our subgroup analysis based on statin type, the I^2^ values of fluvastatin and pravastatin were significantly decreased compared with that of the overall result (Figure [S19](#jah32066-sup-0001){ref-type="supplementary-material"}). Furthermore, the dose of statins also differed among studies. In addition to the fact that these factors may contribute to the heterogeneity, some other factors, such as ethnicity,[14](#jah32066-bib-0014){ref-type="ref"} ultraviolet exposure, and education level, may also lead to heterogeneity.[38](#jah32066-bib-0038){ref-type="ref"}, [39](#jah32066-bib-0039){ref-type="ref"}, [40](#jah32066-bib-0040){ref-type="ref"} The difference in the ascertainment method of statin use was also a source of heterogeneity. Klein et al[15](#jah32066-bib-0015){ref-type="ref"} and Tan et al[16](#jah32066-bib-0016){ref-type="ref"} determined statin use according to patient interviews, whereas in other studies, statin use was ascertained according to computerized prescription records.[12](#jah32066-bib-0012){ref-type="ref"}, [13](#jah32066-bib-0013){ref-type="ref"}, [14](#jah32066-bib-0014){ref-type="ref"}, [17](#jah32066-bib-0017){ref-type="ref"}, [18](#jah32066-bib-0018){ref-type="ref"}, [19](#jah32066-bib-0019){ref-type="ref"}, [20](#jah32066-bib-0020){ref-type="ref"}, [21](#jah32066-bib-0021){ref-type="ref"}, [22](#jah32066-bib-0022){ref-type="ref"} However, even if prescription records or interviews showed that a patient was prescribed statins, differences in patient compliance may have resulted in different degrees of exposure, which may have led to heterogeneity. Some previous studies have found that statin use has different effects on different types of cataract;[35](#jah32066-bib-0035){ref-type="ref"}, [37](#jah32066-bib-0037){ref-type="ref"} therefore, heterogeneity may result from study variations in the types of cataract and the proportions of statin types used.

Two of the included studies reported that statin use was protective against cataracts.[15](#jah32066-bib-0015){ref-type="ref"}, [16](#jah32066-bib-0016){ref-type="ref"} These 2 studies are long‐term prospective cohort studies that followed patients using periodical lens photographs. Such a design tends to achieve reliable results. However, these studies had limitations. The rate of loss to follow‐up was relatively high in these 2 studies (more than 20% at the 5th year).[15](#jah32066-bib-0015){ref-type="ref"}, [16](#jah32066-bib-0016){ref-type="ref"} Moreover, the sample sizes of these 2 studies were relatively small.

The analysis of the RCTs indicated that statin use does not increase the risk of cataract. Most of the individual results of included studies are consistent with this overall result. In the subgroup analyses by age and follow‐up duration, no association was observed between statin use and cataract risk (Table [S7](#jah32066-sup-0001){ref-type="supplementary-material"}). The SEAS study reported that patients with aortic stenosis that were treated with simvastatin and ezetimibe had a lower risk of cataract than did patients treated with placebo.[27](#jah32066-bib-0027){ref-type="ref"} Because the treatment group received ezetimibe, which is a cholesterol‐lowering agent, this result may be overlooked in this study.[41](#jah32066-bib-0041){ref-type="ref"} Heterogeneity may have also arisen from this study.

The strengths of our meta‐analysis include the analysis of both observational studies and RCTs and the large sample size. Despite its strengths, there are several limitations of our analysis. First, evidence of among‐study heterogeneity of the observational studies was apparent. Although we performed subgroup analyses in an attempt to identify the sources of heterogeneity, these variables could not fully explain the observed heterogeneity, suggesting that other unknown, confounding variables might be responsible. Second, the confounding factors varied among the included studies.

Because of the limitations of observational studies and RCTs, large, multicenter, pragmatic, prospective observational studies or registries should be performed in the future to assess the risk of cataracts. The primary end points should include not only cardiovascular diseases but also total comorbidity. Moreover, patients should be stratified according to baseline confounders. Cataracts should be confirmed by objective serial testing using validated tools, and per‐protocol analysis should be used to determine the protocol effects on results. Finally, investigators should attempt to characterize and follow the outcomes of those patients who drop out of the trials.[35](#jah32066-bib-0035){ref-type="ref"}

Conclusion {#jah32066-sec-0017}
==========

Based on the present meta‐analysis of these studies, we could only conclude that there is no clear evidence showing that statin use increases the risk of cataract. The most likely case is that there is no association. Because of the considerable benefits of statins in cardiovascular patients, this issue should not deter the use of statins.
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